PFE Oct 2024 24.000 put
| Previous close | 0.1900 |
| Open | 0.1900 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 24.00 |
| Expiry date | 2024-10-18 |
| Day's range | 0.1900 - 0.1900 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
Associated Press FinanceFDA advisers urge targeting JN.1 strain in recipe for fall's COVID vaccines
Government advisers Wednesday said it’s time to update the recipe for the COVID-19 vaccines Americans will receive in the fall -- targeting a version of the ever-evolving coronavirus called JN.1. Moderna, Pfizer and Novavax all have tested doses updated to match the JN.1 variant that became dominant last winter. FDA’s advisers voted Wednesday that the next vaccine should come from the JN.1 “lineage” or family.
GlobeNewswireRelay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Combination with RLY-2608
Initial triplet combination of RLY-2608 + atirmociclib + fulvestrant to be evaluated in patients with PI3Kα-mutated HR+/HER2- metastatic breast cancer; initiation planned by end of 2024CAMBRIDGE, Mass., June 05, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced a clinical trial collaboration with Pfizer Inc. (NY
ZacksFDA Panel to Consider Updating COVID-19 Jabs for New Virus Strains
An FDA panel meeting is scheduled on Jun 5 to consider if COVID-19 vaccines should be updated to target the WHO-recommended JN.1 variant or the KP.2 variant which is the currently dominating strain in the country.
